Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Decitabine for Coronavirus (COVID-19) Pneumonia- Acute Respiratory Distress Syndrome (ARDS) Treatment: DART Trial (DART)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04482621
Recruitment Status : Recruiting
First Posted : July 22, 2020
Last Update Posted : May 12, 2021
Sponsor:
Information provided by (Responsible Party):
Johns Hopkins University

Brief Summary:
This is a a randomized double blind placebo controlled Phase 2 trial with a 12 patient lead-in to evaluate safety, prior to full enrollment to an additional 28 patients (for a total of 40 patients) to assess efficacy of decitabine in the treatment of critically ill patients with COVID-ARDS. The patients will be randomized in a 1:1 ratio to receive standard of care plus Decitabine or standard of care plus saline based placebo. The primary objective is to determine safety and efficacy of decitabine for COVID-19 ARDS based on clinical improvement on a 6-point clinical scale.

Condition or disease Intervention/treatment Phase
COVID-19 Drug: Decitabine Other: Placebo Saline Phase 2

Detailed Description:

This is a randomized double blind placebo controlled Phase 2 trial with a 12 patient lead-in to evaluate safety, prior to full enrollment to an additional 28 patients (for a total of 40 patients) to assess efficacy of decitabine in the treatment of critically ill patients with COVID-ARDS. The patients will be randomized in a 1:1 ratio to receive standard of care plus Decitabine or standard of care plus saline based placebo.

Eligible patients will receive decitabine 10 mg/m2 daily for 5 days, 1 cycle only. This is a dose that is half the FDA approved dose for myelodysplastic syndrome (MDS), and using a single cycle.

If less than 2 of the first 6 (treatment arm) patients experience an unacceptable toxicity, defined as any treatment related grade III or higher adverse events, as per section 5.7, within 15 days of initiation of treatment, the drug is safe to continue. If the investigators observe more than 33% patients with unacceptable toxicity, the investigators will pause the accrual pending safety evaluation. After validating safety, the investigators will enroll additional 28 patients towards the primary efficacy endpoint. The investigators will monitor safety throughout the trial by monitoring clinical hematologic, chemistry, vital signs, respiratory parameters, medications, and clinical changes daily as per the schedule of procedures.

Bio samples from peripheral blood mononuclear cell (PBMC) and Mini Bronchoalveolar lavage (BAL) will be collected and stored for secondary analysis and mini BAL will only be collected as an optional sub-study for patient consented to a separate study protocol either at time-point of for-cause clinically indicated bronchoscopy, or for subjects consented to a separate Bronchoalveolar lavage (BAL) interventional study, under the auspices of that protocol. For research bio specimens required after study drug initiation, a window period of +/-24 hours while inpatient, and +/- 4 days for outpatient monitoring will be permitted.

These objectives will allow for the planning of subsequent phase 3 studies, and strengthen implementation of a multi-center randomized trial should this study confirm safety, and suggest efficacy of therapy.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 40 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: This is a randomized double blind placebo controlled Phase 2 trial with a 12 patient lead-in to evaluate safety, prior to full enrollment to an additional 28 patients (for a total of 40 patients) to assess efficacy of decitabine in the treatment of critically ill patients with COVID-ARDS. The patients will be randomized in a 1:1 ratio to receive standard of care plus Decitabine or standard of care plus saline based placebo.
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Decitabine for COVID-19 Pneumonia-ARDS Treatment: DART Trial
Actual Study Start Date : September 14, 2020
Estimated Primary Completion Date : September 2021
Estimated Study Completion Date : November 2021


Arm Intervention/treatment
Active Comparator: Decitabine + Standard of Care (SOC)
Study drug Decitabine will be administered via Intravenous injection. Dosage Regimen: 10mg/m^2/day IV day x 5 days (1 cycle only)
Drug: Decitabine

Study duration is 6 weeks after the last dose of study drug. Number of study visits is dependent on Length of hospitalization of study participant. Study visits are scheduled on days 0-7, 11, 15, 29, and may occur via telemedicine or inpatient assessment or outpatient assessment in COVID recovered participants.

Decitabine will be administered via Intravenous Administration 10/mg/m^2/day Dosage: 10mg/m^2/day IV day x 5 days (1 cycle only)

Other Names:
  • 5-aza-2'- deoxycytidine
  • DACOGEN

Placebo Comparator: Standard of Care (SOC) + Placebo
Saline based placebo will be administered via Intravenous injection. Dosage Regimen: 10mg/m^2/day IV day x 5 days (1 cycle only)
Other: Placebo Saline
Saline based placebo will be administered via Intravenous injection. Dosage Regimen: 10mg/m^2/day IV day x 5 days (1 cycle only)




Primary Outcome Measures :
  1. Change in clinical state as assessed by a 6-point ordinal scale [ Time Frame: Baseline and daily up to day 10 ]

    Clinical improvement within 10 days since start of treatment, defined as a decrease of at least 1 point within 10 days from baseline on a six-point ordinal scale:

    1. Not hospitalized/discharged;
    2. Hospitalized, not requiring supplemental oxygen;
    3. Hospitalized, requiring supplemental oxygen;
    4. Hospitalized, requiring nasal high-flow oxygen therapy, noninvasive mechanical ventilation, or both;
    5. Hospitalized, requiring invasive mechanical ventilation, extra-corporeal membrane oxygenation (ECMO), or both; and
    6. Death.


Secondary Outcome Measures :
  1. Safety as assessed by adverse events [ Time Frame: Up to 6 weeks ]
    Safety assessments using adverse events will be monitored daily while inpatient and weekly through end of study at week 6 once discharged from hospital. They will be monitored and graded using Common Terminology Criteria Adverse Events version 5.0.

  2. Change in oxygenation index [ Time Frame: Daily, up to 6 weeks ]
    Oxygenation index is used to assess severity of hypoxic respiratory failure. (OI = mean airway pressure (MAP) × Fraction of inspired oxygen (FiO2) × 100÷ partial pressure of oxygen (PaO2). This will be measured daily while subject is on mechanical ventilation up to 6 weeks.

  3. Change in fraction of inspired oxygen [ Time Frame: Up to day 29 ]
    Fraction of inspired oxygen in the oxygen delivery system during hospital stay. Measured at 8 am daily during hospital stay and then weekly until day 29.

  4. Time (days) to clinical improvement [ Time Frame: Up to 6 weeks ]

    Number of days for subject that have a reduction by at least 2 point from baseline on a six point ordinal scale:

    1. Not hospitalized/discharged;
    2. Hospitalized, not requiring supplemental oxygen;
    3. Hospitalized, requiring supplemental oxygen;
    4. Hospitalized, requiring nasal high-flow oxygen therapy, noninvasive mechanical ventilation, or both;
    5. Hospitalized, requiring invasive mechanical ventilation, extra-corporeal membrane oxygenation (ECMO), or both; and
    6. Death.

  5. Overall survival [ Time Frame: Up to 6 weeks ]
    Patients status of alive versus death at completion of study follow up period, i.e. 6 weeks from start.

  6. Length of stay in hospital [ Time Frame: Till hospital discharge, up to 6 weeks ]
    Duration of days from baseline to hospital discharge.

  7. Ventilator free days [ Time Frame: Up to 6 weeks ]
    For subjects who received mechanical ventilation, total number of days from baseline to end of study at 6 weeks that subject was not on mechanical or non invasive mechanical ventilation.

  8. Time to Polymerase chain reaction (PCR) negativity [ Time Frame: Up to 6 weeks ]
    If viremic at starting date of decitabine - time from baseline to 1st recorded negative COVID nucleic acid amplification (NAT) based assay, measured in days.

  9. Percentage of patients with National Early Warning Score 2 of 3 or more [ Time Frame: Weekly while patient is in hospital, up to 6 weeks ]
    Determines the degree of illness of a patient and prompts critical care intervention. This composite score includes Respiratory Rate, Temperature, oxygen Saturation, Blood Pressure, Oxygen inspired and cognitive status. This will be measured at baseline and weekly while patient is in hospital.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. ≥18 years
  2. Use of Intermittent Mechanical Ventilation, non-invasive mechanical ventilation (NIMV) or High Flow Nasal Cannula.
  3. Have ARDS or Acute Lung Injury physiology confirmed by Pao2/Fio2 ratio of < 300
  4. Severe Acute Respiratory Distress Syndrome (SARS) - Coronavirus (CoV-2) determined by lab polymerase chain reaction assay in either upper or lower respiratory tract sampling (e.g. bronchoalveolar lavage or nasopharyngeal swab)
  5. If childbearing age: agree to practice effective birth control from screening until at least 180 days after last dose

Exclusion Criteria:

  1. Hematologic cytopenias: Absolute Neutrophil Count (ANC) <1500/mm3, Hgb<7.0 and/or platelets <100,000/mm3
  2. Subjects receiving or enrolled in clinical trial for other investigational treatment for SARS- 2-CoV.
  3. Active malignancy, solid tumors, and current or recent chemotherapy
  4. Concomitant use of nonbiologic immunosuppressants (e.g. Janus Kinase (JAK) inhibitors, Bruton's Tyrosine Kinase (BTK) inhibitors)
  5. Active HIV viremia, or any other uncontrolled secondary infection.
  6. Concurrent immunomodulating biologics or use of Palifermin, Dipyrone, Deferiprone
  7. Subjects with severe sepsis with vasopressors or extrapulmonary organ failure:
  8. Aspartate aminotransferase (AST) / alanine aminotransferase (ALT) /alkaline phosphatase (ALK) Phos ≥3x upper limit of normal (ULN) and Total Bilirubin (TBILI) ≥2x ULN; or Creatinine clearance <30 mL/min
  9. Pregnant women or women who are breastfeeding
  10. Any Condition, per opinion of PI that would affect subject safety and/or compliance
  11. Prior hypersensitivity to decitabine

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04482621


Contacts
Layout table for location contacts
Contact: Joby Mathew, DPT, MS 443-416-7573 jmathe27@jhmi.edu
Contact: Katrina Bazemore kbazemo5@jhmi.edu

Locations
Layout table for location information
United States, Maryland
Johns Hopkins University Recruiting
Baltimore, Maryland, United States, 21287
Contact: Joby Mathew, DPT, MS    410-550-6458    jmathe27@jhmi.edu   
Principal Investigator: Franco D'Alessio, M.D.         
Sponsors and Collaborators
Johns Hopkins University
Investigators
Layout table for investigator information
Principal Investigator: Franco D'Alessio, M.D Johns Hopkins UIniversity
Publications:

Layout table for additonal information
Responsible Party: Johns Hopkins University
ClinicalTrials.gov Identifier: NCT04482621    
Other Study ID Numbers: IRB00247544
First Posted: July 22, 2020    Key Record Dates
Last Update Posted: May 12, 2021
Last Verified: May 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Johns Hopkins University:
COVID-19
Additional relevant MeSH terms:
Layout table for MeSH terms
Pneumonia
Lung Diseases
Respiratory Tract Diseases
Respiratory Tract Infections
Decitabine
Antimetabolites, Antineoplastic
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Enzyme Inhibitors